SCYX (scynexis.com) Bathi resik saben saham (EPS TTM)

Competition risks and cheap generics are constraining revenue, yet the transition to a royalty-based licensing model has minimized costs. The change in the rolling annual EPS demonstrates actual plan execution, and -1.19 becomes the new value for this metric. The resilience of pharmacy channels and control over raw material supply chains allow SCYNEXIS, Inc. (SCYX) to maintain high production margins for antifungal agents.

Professional capital evaluates the profile of SCYNEXIS, Inc. (SCYX) through the dynamics of real income generation. The fundamental TTM net income per share metric aggregates earnings over the last four quarters, distributing them across the total volume of issuance. Analyzing this curve allows for the rapid identification of declining profitability. For this developer of innovative antifungal agents, such a metric reflects the efficiency of drug commercialization within the hospital and pharmacy segments. Steady growth of this indicator confirms the investment reliability of the asset.